SUBA™ Bioavailability Technology
SUBA technology is a novel technology for enhancing the bioavailability of poorly soluble drugs. The technology utilizes a solid dispersion of drug in a polymer to improve the absorption of drugs in the gastrointestinal tract to achieve “super bioavailability” compared to conventional formulations. This dispersion improves the dissolution of poorly soluble drugs compared to their normal crystalline form.
Potential benefits of SUBA technology include:
- Increased bioavailability
- Reduced intra/inter-patient variability
- Reduced side effects
SUBA technology has been successfully applied to improve the bioavailability of the poorly soluble and highly variable anti-fungal drug itraconazole, and has recently received regulatory approval to market this improved formulation of itraconazole (brand name Lozanoc®) in Australia and a number of European markets.
Itraconazole drug substance prior to processing.
SUBA™ Itraconazole solid dispersions containing 40% Itraconazole: 60% HP-50